Immunic Therapeutics

Name: Immunic Therapeutics
Address: 1200 Avenue of the Americas, Suite 200, New York, NY, NY10036, US
Telephone: +4989208047700

Home
United States
New York, NY
Immunic Therapeutics

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of select

06/18/2026

📍Will you be at next week?

will be in and is looking forward to connecting with industry peers, partners, colleagues, and the broader community.

If you are attending, we would love to connect and exchange ideas. Feel free to reach out! 🤝

I am Biotech

06/17/2026

Behind every clinical program is a team of experts driving its various elements forward ✨

🤝 In recent months, 's organization has grown significantly, adding expertise across , clinical data interpretation, and scientific exchange. This growth strengthens our ability to engage with investigators, clinicians, and advocacy partners to ensure that emerging evidence ultimately serves the needs of people living with neurological diseases.

As our organization continues to evolve, we remain committed to building credible, science-driven capabilities to support our development programs and contribute to advancing care in .

📍 Meet members of our Medical Affairs team at the European Academy of Neurology ( ) Congress in , Switzerland (June 27-30) at booth E42, and check out our current job offerings here: www.imux.com/career

European Academy of Neurology

06/15/2026

🧠 Can treatment of ( ) go beyond and address what drives long-term disability?

Our President & COO Jason Tardio recently joined Chris Leidli on the Rx for Biotech podcast to discuss how the field is evolving and why remains a key goal in MS.

🎙️ In the conversation, Jason outlines calcium, our lead investigational therapy currently in phase 3 clinical trials for relapsing MS ( ), and its dual mode of action. Designed to not only target the inflammatory component of the disease but also the underlying, smoldering , this approach aims to address key drivers of MS disease progression.

Dive into the discussion where MS research may be heading: 👉 https://bit.ly/4xC3DjQ

06/11/2026

🧠 "Beyond relapse control"

💡 As our understanding of ( ) evolves, so does the way we think about treating it. In this recent article published in Drug Discovery & Development, 's Dr. Andreas Muehler, Dr. Hella Kohlhof and Dr. Evelyn Peelen discuss how multiple biological processes may contribute to disease activity and in MS, and what this could mean for future treatment approaches.

👉 Read the full article here on page 86-89: https://bit.ly/4umv7qB

06/10/2026

📢 Immunic will participate in key conferences this June, engaging with the , and communities.

💼 June 15-16 | H.C. Wainwright Neuro Perspectives Expert Summit (New York & virtual): Erik Lundgren, CEO, and Jason Tardio, President & COO, will participate in a chat. The presentation will be available via the conference platform and on ’s IR website.

🌐 June 22-25 | BIO International Convention (San Diego): Members of our management team will participate in activities.

🔬 June 22-25 | - Medicinal Frontiers Symposium (Dublin): Dr. Christian Gege, Global Head of , will present work related to .

🧠 June 27-30 | European Academy of ( ) Congress (Geneva): Members of our medical team will be present at E42.

👉 View all details here: https://bit.ly/4eeu2ve

I am Biotech, The European Federation for Medicinal Chemistry - EFMC, European Academy of Neurology

06/09/2026

🎙️ A new episode of the Beyond podcast, hosted by , featuring ’s Dr. Daniel Vitt.

🧠 The conversation focuses on ( ), a disease affecting nearly three million people worldwide, and the ongoing need for improved treatment options.

Daniel shares his path into , discusses what living with MS means for patients, and explains the science behind Immunic’s lead development program, calcium. The interview also covers insights from our phase 2 and phase 3 trials, as well as perspectives on the future of care.

👉 Tune in: https://bit.ly/3Q5FdOI

06/03/2026

Thank you to everyone who connected with us at this year’s Annual Meeting. It was a great opportunity to engage with the ( ) community, exchange perspectives and discuss emerging research. 🤝

At our booth and during the poster sessions, we shared additional analyses from our phase 2 trial evaluating calcium in progressive MS ( ).

Highlights:
🧾 Our late-breaking poster introduced a novel unified endpoint for assessing confirmed disability changes in PMS trials

📊 Patient-reported outcome data from CALLIPER favored vidofludimus calcium over placebo

🛡️ Additional CALLIPER data supports the favorable and profile of vidofludimus calcium

Learn more about the data presented at CMSC: https://bit.ly/3Q77Pac

The Consortium of Multiple Sclerosis Centers

06/02/2026

🚶‍♀️ May 50K Challenge for MS – completed ✅

Over the course of May, colleagues across got active in their own way, all in support of people living with ( ). 🚴‍♂️🏊‍♀️ With everyone reaching their individual targets, Immunic doubled the initial donation.

A meaningful initiative that brought together movement, , and support for the MS community. Well done, team – to be continued. 💙

Deutsche Multiple Sklerose Gesellschaft, Bundesverband e.V. , MS Society UK , Stichting MS Research , Multiple Sclerosis International Federation , Multiple Sclerosis Ireland ,

06/01/2026

✨ Marking Erik Lundgren’s first day as the new Chief Executive Officer of , featured on the tower in . 🏙️

We look forward to this next phase of growth. Thank you, Nasdaq, for the continued support and welcome to , Erik.

Address

1200 Avenue Of The Americas, Suite 200
New York, NY
NY10036

Telephone

+4989208047700

Website

https://www.imux.com/

Alerts

Be the first to know and let us send you an email when Immunic Therapeutics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your business to be the top-listed Business in New York?